<code id='A6DCE257D4'></code><style id='A6DCE257D4'></style>
    • <acronym id='A6DCE257D4'></acronym>
      <center id='A6DCE257D4'><center id='A6DCE257D4'><tfoot id='A6DCE257D4'></tfoot></center><abbr id='A6DCE257D4'><dir id='A6DCE257D4'><tfoot id='A6DCE257D4'></tfoot><noframes id='A6DCE257D4'>

    • <optgroup id='A6DCE257D4'><strike id='A6DCE257D4'><sup id='A6DCE257D4'></sup></strike><code id='A6DCE257D4'></code></optgroup>
        1. <b id='A6DCE257D4'><label id='A6DCE257D4'><select id='A6DCE257D4'><dt id='A6DCE257D4'><span id='A6DCE257D4'></span></dt></select></label></b><u id='A6DCE257D4'></u>
          <i id='A6DCE257D4'><strike id='A6DCE257D4'><tt id='A6DCE257D4'><pre id='A6DCE257D4'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:9554
          Mark Lennihan/AP

          A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

          The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

          advertisement

          Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more
          Trump's false claims about Georgia's 2020 election long debunked
          Trump's false claims about Georgia's 2020 election long debunked

          43:58FormerPresidentDonaldTrumpspeakswiththepressattheIowaPorkProducersboothduringthe2023IowaStateFa

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          States increasingly look to regulate hospital facility fees

          Hospitalshaveacquiredalotofphysicianofficesandhaveaddedfacilityfeestotheircharges.JEFFPACHOUD/AFPvia